Dupilumab Demonstrates Significant Improvements in COPD Patients with Type 2 Inflammation in Second Phase 3 Clinical Trial
by A recent Phase 3 clinical trial has shown that dupilumab, a monoclonal antibody, significantly reduces disease activity and improves lung function in chronic obstructive pulmonary …